Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-1 antibody plus albumin-bound paclitaxel for recurrent/refractory extranodal NK/T-cell lymphoma
ChiCTR2000031158Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel in Extranodal natural killer/T-cell lymphoma, nasal type (ENKTL), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: Objective response rate. Planned start May 2020; status: not yet recruiting.
02
Drugs
paclitaxel
03
Conditions
Extranodal natural killer/T-cell lymphoma, nasal type (ENKTL)
Beyond the preview
Go deeper on ChiCTR2000031158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000031158.